Quanterix’ Simoa Technology Supports 42 Scientific Presentations at MSVirtual2020
September 10 2020 - 9:00AM
Business Wire
Company’s ultra-sensitive platform continues to
facilitate important advances that harness biomarkers to identify,
monitor and validate treatment pathways for Multiple Sclerosis
(MS)
Quanterix Corporation (NASDAQ: QTRX), a company digitizing
biomarker analysis to advance the science of precision health,
today announced that its ultra-sensitive Simoa® technology has been
used by leading research teams to power 42 studies presented at the
8th Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020, taking place
remotely from Sept. 11-13. Additionally, Quanterix will be
sponsoring the event with a virtual exhibit booth. The 2020 event
marks Quanterix’ fifth consecutive year of supporting MS research
through its continued participation at this meeting and its third
year as a sponsoring organization.
“Although the pandemic has shifted global attention to a
different fight, chronic conditions like MS continue to impact the
lives of millions,” said Kevin Hrusovsky, Chairman, Chief Executive
Officer and President, Quanterix and Founder, Powering Precision
Health (PPH). “We are grateful to the researchers who continue to
advance their work during these uncertain times and are honored our
Simoa technology continues to play an important role in powering
these important breakthroughs. By applying the unprecedented
sensitivity of our platform to their MS research, scientists have
made significant strides toward diagnosing, monitoring and treating
the disease that will be on full display this year.”
This year’s event will feature more than 40 Simoa-powered
posters and presentations that look at various biomarkers used in
the detection and treatment of neurodegenerative diseases –
including serum neurofilament light (sNfL) – and evaluate how the
biomarkers can be used to impact MS. Specifically, this year’s
research presentations will focus on defining baseline levels of
sNfL and how biomarkers are being used in MS monitoring and
treatment in research and in the clinic.
Quanterix will also be participating in a special Encore event
with Dr. David Leppert, Professor of Neurology at the University of
Basel, based on his late-breaking abstract, “Neutrophil granulocyte
markers in cerebrospinal fluid differentiate NMOSD and anti-MOG
antibody associated disease from MS in acute disease phase,” on
Saturday, Sept. 26. Dr. Leppert will illustrate how Simoa enabled
his team to study biomarkers critical to distinguishing MS from
Neuromyelitis Optica Spectrum Disorder (NMOSD) and anti-myelin
oligodendrocyte glycoprotein (anti-MOG), two immune-mediated
inflammatory conditions that require lengthy methods for
differentiation using traditional cell-based laboratory
methods.
Additional late-breaking abstracts include two manuscripts from
Paola Valentino, a biotechnologist and specialist in clinical
biochemistry at the Neuroscience Institute Cavalieri Ottolenghi,
and one from Dr. Antonio Bertolotto, head physician and neurologist
at San Luigi Gonzaga Hospital. Valentino will present, “Normal
serum NfL levels: a proposal of cut-off strategy definition for the
clinical practice” (LB1219), and “Real-life experience with sNfL in
Multiple Sclerosis patients, as monitoring and treatment decision
biomarker” (LB1220). Dr. Bertolotto will discuss the proposal,
“Applicability of sNfL in Multiple Sclerosis as additional measure
in clinical practice and implications in NEDA-3 evaluation”
(LB1221).
Attendees are encouraged to visit Quanterix’ sponsored booth to
speak with company experts about the advantages of Simoa technology
along with its robust menu of ultra-sensitive, blood-based assays,
including neurofilament light chain (NfL) and inflammatory
cytokines, to support MS diagnosis, monitoring and treatment
efforts. More information about Simoa’s MS capabilities will be
displayed prominently in the MSVirtual Industry Hub alongside other
sponsoring companies, such as Biogen, Novartis, Bristol Myers
Squibb and EMD Serono.
To learn more about Quanterix’ involvement in the virtual
meeting, visit
https://www.quanterix.com/resources/conferences/actrimsectrims-2020.
To find out more about Simoa® technology, visit
https://www.quanterix.com/technology. To view its wide-range of
neurology assays, click here.
About Quanterix
Quanterix is a company that’s digitizing biomarker analysis with
the goal of advancing the science of precision health. The
company’s digital health solution, Simoa®, has the potential to
change the way in which healthcare is provided today by giving
researchers the ability to closely examine the continuum from
health to disease. Quanterix’ technology is designed to enable much
earlier disease detection, better prognoses and enhanced treatment
methods to improve the quality of life and longevity of the
population for generations to come. The technology is currently
being used for research applications in several therapeutic areas,
including oncology, neurology, cardiology, inflammation and
infectious disease. The company was established in 2007 and is
located in Billerica, Massachusetts. For additional information,
please visit https://www.quanterix.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as "may," "will," "expect," "plan," "anticipate,"
"estimate," "intend" and similar expressions (as well as other
words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
Forward-looking statements in this news release are based on
Quanterix’ expectations and assumptions as of the date of this
press release. Each of these forward-looking statements involves
risks and uncertainties. Factors that may cause Quanterix’ actual
results to differ from those expressed or implied in the
forward-looking statements in this press release are discussed in
Quanterix’ filings with the U.S. Securities and Exchange
Commission, including the "Risk Factors" sections contained
therein. Except as required by law, Quanterix assumes no obligation
to update any forward-looking statements contained herein to
reflect any change in expectations, even as new information becomes
available.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200910005112/en/
Media Contact: PAN Communications Staci Didner, (407)
734-7325 quanterix@pancomm.com
Investor Relations Contact: Stephen Hrusovsky (774)
278-0496 shrusovsky@quanterix.com
Quanterix (NASDAQ:QTRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Quanterix (NASDAQ:QTRX)
Historical Stock Chart
From Apr 2023 to Apr 2024